Abstract
Gefitinib ('Iressa', ZD1839) has promising antitumor activity in non-small cell lung cancer (NSCLC). However, patients with advanced NSCLC have few treatment options available if they are refractory to gefitinib. We describe four cases of patients with advanced NSCLC who previously responded to gefitinib and obtained significant tumor regression through retreatment with other cytotoxic agents. Gefitinib might restore chemosensitivity to previously chemorefractory patients.
| Original language | English |
|---|---|
| Pages (from-to) | 547-549 |
| Number of pages | 3 |
| Journal | Anticancer research |
| Volume | 25 |
| Issue number | 1 B |
| Publication status | Published - Jan 2005 |
Keywords
- Gefitinib ('Iressa', ZD1839)
- Non-small cell lung cancer (NSCLC)
- Vinorelbine
ASJC Scopus subject areas
- Oncology
- Cancer Research
